81 results about "Recombinant vaccines" patented technology

The invention provides a monoclonal antibody capable of recognizing a recombinant EGF-CRM197 vaccine and a preparation method thereof, on the basis of researching, developing and preparing the recombinant EGF-CRM197 vaccine, after the recombinant EGF-CRM197 vaccine is further immunized and inoculated to a mouse, mouse spleen cells and mouse myeloma cells are fused, and the monoclonal antibody capable of recognizing the recombinant EGF-CRM197 vaccine is obtained. And screening a hybridoma cell strain which generates a specific monoclonal antibody for recognizing the recombinant EGF-CRM197 vaccine, and sequencing to obtain an antibody sequence. After the hybridoma cells are cultured in a mouse body, the monoclonal antibody for recognizing the recombinant EGF-CRM197 vaccine can be prepared in vitro through methods of chromatographic purification and the like. The method can be used for detecting the release titer of the recombinant EGF-CRM197 vaccine and evaluating the immune efficacy after the recombinant EGF-CRM197 vaccine is immunized.

The invention discloses a Newcastle disease vaccine strain with high antibody escape ability and a modification method thereof, the cell strain is preserved in China General Microbiological Culture Collection Center on January 19, 2024, the address of the preservation unit is CGMCC No.45870, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the classification name of the strain is Newcastle disease virus strain. The recombinant NDV vaccine strain has the same antigen site as the current NDV gene VII type epidemic strain and has the efficient proliferation efficiency superior to that of a classical vaccine strain La Sota, the thermal stability of the NDV vaccine strain is improved by the constructed recombinant vaccine strain, and the cost of vaccine cold-chain transportation is reduced.

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and / or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention provides an L protein mutated recombinant foot-and-mouth disease virus strain and application thereof in vaccine preparation, and belongs to the technical field of biological medicine. Firstly, it is found that overexpression of CISD2 protein in host cells can inhibit FMDV replication, and an inhibition mechanism is analyzed, specifically, the CISD2 inhibits FMDV replication by inhibiting expression of L protein, especially inducing degradation of the L protein through a proteasome pathway. The invention also identifies a key site for degrading the L protein by the CISD2 protein, the recombinant foot-and-mouth disease virus with the mutated key amino acid site of the L protein is successfully constructed and rescued by introducing amino acid mutation of the key site into the L protein by utilizing a reverse genetic technology, the capabilities of degrading the L protein and inhibiting FMDV replication by the CISD2 protein are eliminated, the virus titer is improved, and the recombinant foot-and-mouth disease virus can be used for preparing the recombinant foot-and-mouth disease virus with the mutated key amino acid site of the L protein. The strain has good production performance and can be used for preparing recombinant foot-and-mouth disease virus strains and recombinant vaccine strains.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The present invention relates to a recombinant vaccine comprising a PIV5-based viral expression vector with a genetic insert, and methods of producing and using the same. The recombinant vaccine comprises a modified bacterial or viral antigen to increase expression of the antigen on the surface of cells (AOS) to increase immunogenicity to the antigen.

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a deadly global disease. Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases.

The use of anti-HPV immunogens and nucleic acid molecules encoding them for the treatment and prevention of RRP is disclosed.SOLUTION: Pharmaceutical compositions, recombinant vaccines comprising the DNA plasmids, and live attenuated vaccines are disclosed, as well as methods of inducing an immune response to treat or prevent RRP.SELECTED DRAWING: Figure 1

The present invention provides a monoclonal antibody that recognizes a recombinant EGF-CRM197 vaccine and a preparation method thereof. Based on the research and development and preparation of a recombinant EGF-CRM197 vaccine, the present invention further immunizes mice with the recombinant EGF-CRM197 vaccine, fuses the mouse spleen cells with mouse myeloma cells, screens and produces a hybridoma cell line of specific monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine, and obtains the antibody sequence after sequencing. After the hybridoma cells are cultured in mice, monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine can be prepared in vitro by methods such as chromatography purification. The present invention can be used for the release potency detection of the recombinant EGF-CRM197 vaccine and for evaluating the immune efficacy after immunization with the recombinant EGF-CRM197 vaccine.

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

The application belongs to the field of vaccines and genetic engineering technology, and relates to an H3N2 canine influenza recombinant virus strain and application thereof. Specifically, the application relates to a recombinant canine influenza vaccine strain which is obtained by recombination of the following genes: an HA gene, an NA gene, a PB1 gene, a PB2 gene, a PA gene, an NP gene, an M gene and an NS gene; wherein the sequence of the HA gene is shown as SEQ ID NO:1; and / or the sequence of the NA gene is shown as SEQ ID NO:2. The application also relates to an H3N2 canine influenza recombinant vaccine and a method for preparing the H3N2 canine influenza recombinant vaccine.

The present invention relates to the field of biomedical technologies, and discloses a long-acting and stable recombinant RSV vaccine based on glycan modification and phase change materials. The vaccine comprises the following components in parts by mass: RSV F protein modified with dynamic glycans: 1 part; multi-stage phase change materials: 3-5 parts, and the multi-stage phase change materials are composed of polyethylene glycol-stearate and lauric acid-cholesterol complex, wherein the mass ratio of polyethylene glycol-stearate to lauric acid-cholesterol is 2-3:1; TLR9 agonist: 0.05-0.15 part; STING agonist: 0.02-0.08 part; amphiphilic block copolymer PLGA-PEG-PLL: 0.5-1.5 parts. The present invention solves the problems of easy inactivation, poor targeting and insufficient immunogenicity of traditional vaccines, is applicable to the prevention and treatment of viral infectious diseases, and has the application potential for large-scale production.

This invention relates to a fusion protein, immunogenic composition, and recombinant vaccine for the prevention of Escherichia coli infection. The invention provides a novel target, PstS, for Escherichia coli vaccine design. Starting from the tertiary structure of PstS and YidR proteins, and combining immunoepitaxes, stable domains of PstS and YidR proteins and their variants are ultimately screened, leading to the construction of a fusion protein. Both the PstS monoantigen protein molecule and the PstS-YidR fusion protein molecule of this invention exhibit good immunogenicity, can reduce tissue lesions caused by Escherichia coli infection, and demonstrate high efficacy in preventing Escherichia coli infection, showing broad application prospects.

The invention relates to a novel fusion protein for preventing and treating mycoplasma bovis infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion protein molecular architecture, which comprises fusion proteins coded by two genes of Bmp and FBA, or fusion proteins coded by three genes of EF-Tu, DnaK and EF-G, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The fusion molecule has good immunogenicity, provides an effective immune protection effect, can eliminate bovine mycoplasma colonization in part of individuals, can be used for preventing and treating bovine mycoplasma infection diseases, and has a wide application prospect in animal husbandry.

The present invention relates to a fusion protein, immunogenic composition, recombinant vaccine, and molecular architecture design and application, etc., for the prevention of Streptococcus Pneumoniae infection. The present invention starts from the protein molecular tertiary structures of ply and PhtD, and via creatively screening, the C-terminal domain of ply protein and the N-terminal domain of phtD protein are finally selected to construct a fusion protein, and the elements such as Fc domain and STABILON are further added. The fusion protein molecule of the present invention can weaken tissue lesions caused by Streptococcus Pneumoniae infection, has good immunogenicity, has an effective preventive and immunoprotective effect, and efficiently prevents Streptococcus Pneumoniae infection. The immunogenic composition, fusion protein, and recombinant vaccine for preventing Streptococcus Pneumoniae infection of the present invention have broad application prospects.

The invention relates to a novel immunogenic composition for preventing and treating pseudomonas aeruginosa infection, a fusion protein, a recombinant vaccine, a molecular architecture design and application. The invention provides a novel fusion molecular architecture, which comprises a fusion protein A coded by three genes of EF-Tu, DnaK and EF-G, or a fusion protein B coded by two genes of PcrV and PilA, or a combination of the fusion protein A and the fusion protein B, and can be used for research and development of nucleic acid vaccines or subunit vaccines. The invention finds that the novel fusion molecule has good immunogenicity, can provide an effective immune protection effect, remarkably inhibits colonization of pseudomonas aeruginosa, and has a wide application prospect.

The invention relates to a fusion protein for preventing klebsiella pneumoniae infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design, application and the like. The invention provides a vaccine for independently expressing a PstS antigen and a vaccine for expressing a fusion protein of YidR-PstS or PstS-YidR, and elements such as an Fc structural domain and STABILON are added. The invention also provides corresponding recombinant nucleic acid, a gene expression cassette, a vector, a host cell, a pharmaceutical composition, a vaccine, application and the like. The vaccine can weaken tissue lesions caused by klebsiella pneumoniae infection, has good immunogenicity, plays effective prevention and immune protection roles, efficiently prevents klebsiella pneumoniae infection, and has wide application prospects.

The application provides a standard plasmid for detecting the copy number of exogenous genes of a recombinant CVA10 vaccine, and a preparation method and application thereof. The standard plasmid of the application comprises an endogenous gene MOX fragment SEQ ID No. 1, an exogenous gene P1 fragment SEQ ID No. 2 and an exogenous gene 3CD fragment SEQ ID No. 3 which are connected in series in a cloning vector. The application constructs the standard plasmid, adopts Taqman probe-fluorescence quantitative PCR method, and simply, quickly, absolutely quantitatively and accurately analyzes the copy number of inserted exogenous genes, so that the detection time of the determination of the copy number of exogenous genes of the recombinant CVA10 vaccine is effectively shortened, repeated operation is facilitated, and the determination of the copy number of exogenous genes of the recombinant CVA10 vaccine based on the Hansenula platform and the verification of the genetic stability of the exogenous genes of the recombinant CVA10 vaccine have a wide application prospect.

The invention relates to a fusion protein for preventing salmonella infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design, application and the like. According to the invention, three fusion proteins, namely PstS-LpfB, PstS-YidR and LpfB-SinH, which can be smoothly expressed in eukaryotic cells are selected to carry out animal immune experiments, so that the protection effect is verified. The invention finds that fusion protein molecules such as PstS-LpfB and the like can weaken tissue lesions caused by salmonella infection, have good immunogenicity, play a role in effective prevention and immune protection, efficiently prevent salmonella infection and have wide application prospects.

The application discloses a CMV virus-like particle for producing a VLP recombinant vaccine and a preparation method thereof, the CMV virus-like particle is obtained by cloning a C-terminal G4SLPETG modified plant virus cucumber mosaic virus CMV capsid gene into a prokaryotic expression vector to obtain a recombinant expression vector, the recombinant expression vector is transfected into E. coli BL21 (DE3), and expression is obtained through the recombinant E. coli BL21 (DE3); and the amino acid sequence of the C-terminal G4SLPETG modified CMV is SEQ ID NO. 1. Test proves that the recombinant strain constructed by the application is stable to expression of an exogenous protein. The recombinant protein expressed by the application is used for preparing a virus-like particle for antigen coupling, the coupling efficiency is high, the antigen purity is high, the safety is good, the virus-like particle is not pathogenic to mice and other animals, and the safety evaluation is easy.

The present application relates to the fusion protein, immunogenic composition, recombinant vaccine and application for preventing acinetobacter baumannii infection, etc. The present application screens and obtains four groups of antigen combination fusion protein mRNA vaccines of AdeK-LolB, Omp22-HphA, Omp22-LolB and CsuE-CsuAB, which show excellent effects in the mouse acinetobacter baumannii infection model. Compared with the nucleic acid vaccine encoded by the Omp22-Omp38 fusion protein known in the prior art and having excellent effects itself, the nucleic acid vaccine has better immunization effects and protective effects for preventing acinetobacter baumannii infection in reducing acinetobacter baumannii colonization and reducing the degree of lesions caused by infection, and has a wide application prospect.

The present invention relates to an immunogenic composition against Neisseria meningitidis serogroup B in liquid form and a reconstituted vaccine against Neisseria meningitidis serogroups A, B, C, W135, and Y comprising this liquid composition. Also provided are kits and methods for the prevention and treatment of Neisseria meningitidis infections and diseases using the immunogenic composition or the reconstituted vaccine.

The invention relates to a fusion protein, an immunogenic composition, a recombinant vaccine and the like for preventing Escherichia coli infection. The invention provides a new target PstS for Escherichia coli vaccine design, starting from a protein molecule tertiary structure of PstS and YidR, combining with immune epitopes and the like, finally screening to obtain a PstS protein, a YidR protein and stable structural domains of variants of the PstS protein and the YidR protein, and constructing to obtain a fusion protein. The PstS single antigen protein molecule or the PstS-YidR fusion protein molecule provided by the invention has good immunogenicity, can weaken tissue lesions caused by Escherichia coli infection, has good immunogenicity, can efficiently prevent Escherichia coli infection, and has a wide application prospect.

The invention discloses a recombinant I-type herpes simplex virus vaccine and application thereof, and belongs to the technical field of vaccines. In particular to a fusion protein which is composed of an antigen molecule gD1, a human immunoglobulin antibody Fc structural domain and a human IgG1 hinge region fragment, the amino acid sequence of the antigen molecule gD1 is shown as SEQ ID NO.6, and a recombinant vaccine is constructed. The recombinant vaccine fuses a virus antigen, an immune globulin heavy chain Fc structural domain and a human IgG1 hinge region fragment, has better capability of being combined with a receptor on the surface of an antigen presenting cell, can activate specific CD4 + T and CD8 + T cells, generates high-titer antibody titer and specific cellular immunity, and can be used for preparing a high-titer antibody. The vaccine can prevent infection and / or reinfection of the herpes simplex type I virus.

This invention relates to the field of vaccine preparation technology, specifically disclosing a VSV-based HTNV vaccine, its preparation method, and its application. The method involves constructing a recombinant plasmid by inserting the nucleotide sequence of the HTNV envelope glycoprotein into the recombinant VSV vector plasmid, followed by packaging and processing to obtain an immunogenic HTNV recombinant VSV vaccine. The HTNV vaccine prepared by this invention provides a novel candidate vaccine for the prevention and treatment of hemorrhagic fever with renal syndrome.

The present invention relates to a viral vector capable of generating a cellular immune response against a spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), characterized in that the viral vector is a Newcastle disease virus (NDV) comprising a nucleotide sequence of SEQ ID NO: 6 or SEQ ID NO: 14 and an exogenous nucleotide sequence encoding antigenic sites of SARS-CoV-2, wherein the exogenous nucleotide sequence comprises a sequence having at least 95% sequence identity with a sequence that translates into the amino acid sequence of SEQ ID NO: 11, wherein the exogenous nucleotide sequence comprises an ectodomain of a SARS-CoV-2 S protein fused with a transmembrane domain and a cytoplasmic domain of an NDV fusion (F) protein, wherein the polybasic cleavage site of the ectodomain of the S protein is mutated to alanine and amino acids 817, 892, 899, 942,986 and 987 of the ectodomain of the S protein of SEQ ID NO: 11 are prolines, such that the viral vector and antigenic sites are stable after at least 3 consecutive passages in chicken embryo.

The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in Pichia pastoris. More specifically, the invention describes the production of Sm14 Schistosoma mansoni recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of Pichia pastoris promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, Pichia pastoris strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from P. pastoris cells, which can be escalated for their industrial production, were also improved.

The application discloses a recombinant bacillus Calmette-Guerin (BCG) strain and application of the recombinant BCG strain in preparation of a tumor vaccine, wherein the recombinant BCG strain comprises an HPV16 E7 antigen gene with a nucleotide sequence as shown in SEQ ID NO:1; a cytolysin ClyA gene is further fused with the HPV16 E7 to be expressed, and a rBCG-ClyA+E7 recombinant strain is constructed; the recombinant BCG strain rBCG-E7 or rBCG-ClyA+E7 is applied in preparation of a vaccine for treating cervical cancer solid tumors; the anti-tumor effect is verified in a solid tumor model through a subcutaneous injection mode; the ClyA significantly improves the expression efficiency of an exogenous antigen in the BCG, and simultaneously enhances the presentation efficiency of an antigen presenting cell; the recombinant vaccine effectively activates an anti-tumor immune response, and does not cause obvious toxic side effects, thereby providing a safe and effective candidate strategy for immunotherapy of cervical cancer and other HPV related solid tumors.

The invention relates to the field of vaccine research and development, in particular to construction of an Ebola virus recombinant vaccine based on a recombinant measles virus vector, a reverse genetic system and application of the Ebola virus recombinant vaccine. Specifically, a measles virus is used as a vector, and a recombinant vaccine of an Ebola virus related antigen is constructed and expressed through a reverse genetic technology. The vaccine can be used for preventing Ebola virus infection and has a wide application prospect. In addition, the invention also discloses a recombinant measles virus vector, a nucleic acid molecule, a reverse genetic system, a recombinant measles virus particle and application thereof. The measles virus vector is characterized in that a negative strand RNA coding sequence of Ebola virus glycoproteins GP and VP40 is inserted into the measles virus vector. The measles virus vector-based Ebola virus vaccine provided by the invention has high immunogenicity and broad spectrum, and a new idea is provided for the development of novel Ebola virus vaccines. The vaccine provided by the invention is simple in preparation method and can be produced on a large scale in a short time.